Tegobuvir
Names and Identifiers of Tegobuvir
CAS Number |
1000787-75-6 |
|---|---|
MDL Number |
MFCD18251457 |
IUPAC Name |
5-[[6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl]methyl]-2-(2-fluorophenyl)imidazo[4,5-c]pyridine |
InChI |
InChI=1S/C25H14F7N5/c26-19-4-2-1-3-17(19)23-33-21-9-10-37(13-22(21)34-23)12-15-6-8-20(36-35-15)16-7-5-14(24(27,28)29)11-18(16)25(30,31)32/h1-11,13H,12H2 |
InChIKey |
XBEQSQDCBSKCHJ-UHFFFAOYSA-N |
Canonical SMILES |
C1=CC=C(C(=C1)C2=NC3=CN(C=CC3=N2)CC4=NN=C(C=C4)C5=C(C=C(C=C5)C(F)(F)F)C(F)(F)F)F |
UNII |
5NOK5X389M |
UNSPSC Code |
12352100 |
Physical and chemical properties of Tegobuvir
Boiling Point |
558.0±60.0 °C at 760 mmHg |
|---|---|
Density |
1.5±0.1 g/cm3 |
Exact Mass |
517.113770 |
Flash Point |
291.3±32.9 °C |
H Bond Acceptors |
4 |
H Bond Donors |
0 |
Index of Refraction |
1.605 |
LogP |
4.07 |
Molecular Formula |
C25H14F7N5 |
Molecular Weight |
517.401 |
PSA |
56.49000 |
Storage condition |
2-8℃ |
Vapour Pressure |
0.0±1.5 mmHg at 25°C |
Safety Information of Tegobuvir
Applications of Tegobuvir
Tegobuvir's primary application is in the treatment of Hepatitis C virus infections. Its role as a non-nucleoside inhibitor positions it as a crucial component in combination therapies aimed at improving treatment efficacy and minimizing resistance development. Clinical trials have evaluated its safety and effectiveness, particularly in patients who have not responded well to standard therapies.
Biological Activity of Tegobuvir
The biological activity of Tegobuvir is characterized by its ability to inhibit HCV replication effectively. Studies have demonstrated that Tegobuvir displays potent antiviral effects against various HCV genotypes. Its unique mechanism allows it to circumvent some resistance mechanisms that are commonly seen with other antiviral agents, making it a promising candidate for combination therapies in treating chronic hepatitis C.
Physical sample testing spectrum (NMR) of Tegobuvir
Cas:153254-09-2
Cas:1000787-76-7
